| What it is |
No medicine in the bladder after TURBT. Follow-up looks for the cancer coming back so it can be caught early and treated. |
One dose of mitomycin or gemcitabine put into the bladder through a catheter within 24 hours of the TURBT. Held for one to two hours, then voided. |
A weakened germ related to the tuberculosis vaccine. Put into the bladder once a week for six weeks (induction). If it works, more rounds of three weekly doses follow at set times over one to three years (maintenance). |
Gemcitabine put into the bladder for one to two hours, voided, then docetaxel put in for one to two hours, on the same day. Six weekly doses (induction), then maintenance every few months. |
| How it works |
Cystoscopy looks inside the bladder. Urine cytology checks the urine for cancer cells. If something new shows up, it is biopsied or resected. |
The medicine kills any stray cancer cells floating in the bladder right after surgery, before they can stick to the lining. |
BCG triggers a strong immune response inside the bladder. The body's own immune cells attack the bladder lining and any cancer cells there. |
Two chemotherapy medicines with different ways of killing cancer cells, given back to back to hit the lining harder than either one alone. |
| Setting and schedule |
Office cystoscopy every 3, 6, or 12 months depending on your risk group. No instillations. |
One visit in the recovery area or office within 24 hours of TURBT. Just that one dose. |
Outpatient visits to the urologist's office. Six weekly visits, then short maintenance courses (three weekly doses) at 3, 6, 12, 18, 24, 30, and 36 months in the standard schedule. |
Outpatient visits. Six weekly visits for induction, then maintenance instillations on a set schedule, often monthly for several months, then less often. |
| How well it works |
For low-risk bladder cancer (small, solitary, low-grade Ta), the cancer comes back in about 30 to 40 out of 100 people over five years, but it almost never reaches the muscle layer. |
Adding this one dose cuts the early recurrence rate by about 35 to 40% compared with TURBT alone in low and intermediate risk. |
The standard for intermediate and high risk for more than 40 years. With maintenance, lowers both recurrence and the chance the cancer moves into deeper layers. |
For high-grade non-muscle-invasive disease, a large multi-center study reported about 92 out of 100 people free of high-grade recurrence at 6 months with Gem/Doce, compared with about 76 out of 100 with BCG. At 2 years, 81 out of 100 with Gem/Doce and 69 out of 100 with BCG. These are early data and not yet from a head-to-head trial. |
| Side effects in the days after a dose |
None from medicine. Cystoscopy can cause one or two days of burning when you urinate. |
Burning, frequency, blood in urine for a day or two. Skin rash on the lower belly or hands if mitomycin touches skin. |
Burning, frequency, urgency for one to two days. Low-grade fever, fatigue, body aches. Less common: high fever, persistent bladder pain, prostate or testicle inflammation. Rare: a body-wide BCG infection that needs hospital treatment. |
Burning, frequency, urgency for one to two days, similar to BCG but generally less intense. In a comparative cohort, adverse events were 40 out of 100 with Gem/Doce versus 74 out of 100 with BCG. |
| Time commitment over the next 3 years |
Cystoscopy visits only. For low risk, perhaps 4 to 6 visits in 3 years. For higher risk on surveillance, more. |
One extra visit beyond the surveillance schedule. |
Six visits in the first six weeks, then three visits at each of seven maintenance points. About 27 instillation visits over 3 years, on top of cystoscopy. |
Six visits in the first six weeks, then maintenance visits on a set schedule. Roughly similar to BCG in total visits, sometimes fewer. |
| Cost in the United States |
Lowest medicine cost (none). Cystoscopy and urine tests at each visit, usually covered by insurance. |
Low one-time medicine cost. Usually covered. |
The BCG medicine itself is inexpensive when supply is available. Office visits and instillation are usually covered. Out-of-pocket cost depends on your plan. |
Gemcitabine and docetaxel together cost more per dose than BCG. Most plans cover them when BCG is in short supply, but coverage rules and prior authorization vary. |
| Effect on the bladder over time |
None from treatment. The bladder is the same after surveillance visits. |
Almost none after the one dose. |
Years of BCG can leave the bladder smaller, stiffer, or more sensitive in a minority of people. Bladder symptoms between doses can build up. |
Less well studied long-term than BCG, but early data suggest fewer lasting bladder symptoms. |
| What it does NOT do |
Does not lower the chance of recurrence. Catches recurrences early. |
Does not replace BCG or Gem/Doce in intermediate or high risk. Does not lower the chance of cancer reaching the muscle. |
Does not eliminate recurrence; it lowers the odds. Does not work for every patient; some cancers come back despite BCG. |
Does not have decades of follow-up data the way BCG does. Long-term outcomes are still being studied. |
| Best fit when… |
Your cancer is low risk: one small, low-grade Ta tumor, no CIS, no prior bladder cancer. Talk with your urologist about whether the single post-TURBT dose still adds value in your case. |
Your cancer is low or intermediate risk, the TURBT was clean (no perforation, not too much bleeding), and you can receive it within 24 hours. Often given on top of, not instead of, longer treatment in intermediate risk. |
Your cancer is intermediate or high risk, including high-grade Ta, T1, or CIS. BCG is an option whenever supply is available and you can tolerate it. |
Your cancer is intermediate or high risk and BCG is not available locally, or BCG has not worked for you, or you cannot tolerate BCG. Increasingly used as first-line in some centers during the ongoing BCG shortage. |
| When to reconsider |
If a new tumor is found on cystoscopy, the choice opens back up. The new tumor may move you into a higher risk group. |
If your risk group is intermediate or high, you and your urologist will talk about adding induction and maintenance therapy after the single dose. |
If BCG is not available locally, if side effects are too much, or if the cancer comes back during or after BCG. Talk with your urologist about Gem/Doce, other options, or in some cases removing the bladder. |
If the cancer comes back during or after Gem/Doce, your urologist will talk with you about switching to BCG (if available), other intravesical options, FDA-approved bladder-preserving treatments for BCG-unresponsive disease, or removing the bladder. |